| Full Name | John West |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 34 Years |
| Location | 1401 E H St, Mc Cook, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063485290 | NPI | - | NPPES |
| 470748011-12 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 19111 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Healthcare And Hospice | Mccook, NE | Home health agency |
| Community Health Care & Hospice | Mccook, NE | Hospice |
| Community Hospital | Mccook, NE | Hospital |
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Hillcrest Nursing Home | Mccook, NE | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mccook Clinic, P.c. | 0941196125 | 12 |
News Archive
Every time you put on bug spray this summer, you're launching a strike in the ongoing war between humans and mosquitoes - one that is rapidly driving the evolution of the pests. Scientists studying mosquitoes in various types of environments in the United States and in Russia found that between 5 and 20 percent of a mosquito population's genome is subject to evolutionary pressures at any given time - creating a strong signature of local adaptation to environment and humans.
"The entire history of modern medicine can be documented through the NEJM Archive."
IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.
› Verified 8 days ago
| Entity Name | Mccook Clinic, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336290972 PECOS PAC ID: 0941196125 Enrollment ID: O20040225000128 |
News Archive
Every time you put on bug spray this summer, you're launching a strike in the ongoing war between humans and mosquitoes - one that is rapidly driving the evolution of the pests. Scientists studying mosquitoes in various types of environments in the United States and in Russia found that between 5 and 20 percent of a mosquito population's genome is subject to evolutionary pressures at any given time - creating a strong signature of local adaptation to environment and humans.
"The entire history of modern medicine can be documented through the NEJM Archive."
IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.
› Verified 8 days ago
| Entity Name | Community Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588771158 PECOS PAC ID: 9133101629 Enrollment ID: O20040607001378 |
News Archive
Every time you put on bug spray this summer, you're launching a strike in the ongoing war between humans and mosquitoes - one that is rapidly driving the evolution of the pests. Scientists studying mosquitoes in various types of environments in the United States and in Russia found that between 5 and 20 percent of a mosquito population's genome is subject to evolutionary pressures at any given time - creating a strong signature of local adaptation to environment and humans.
"The entire history of modern medicine can be documented through the NEJM Archive."
IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.
› Verified 8 days ago
| Entity Name | Community Hospital Association |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1841204500 PECOS PAC ID: 9133101629 Enrollment ID: O20100908000859 |
News Archive
Every time you put on bug spray this summer, you're launching a strike in the ongoing war between humans and mosquitoes - one that is rapidly driving the evolution of the pests. Scientists studying mosquitoes in various types of environments in the United States and in Russia found that between 5 and 20 percent of a mosquito population's genome is subject to evolutionary pressures at any given time - creating a strong signature of local adaptation to environment and humans.
"The entire history of modern medicine can be documented through the NEJM Archive."
IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John West, MD 1401 E H St, Mc Cook, NE 69001-3432 Ph: (308) 344-4110 | John West, MD 1401 E H St, Mc Cook, NE 69001-3432 Ph: (308) 344-4110 |
News Archive
Every time you put on bug spray this summer, you're launching a strike in the ongoing war between humans and mosquitoes - one that is rapidly driving the evolution of the pests. Scientists studying mosquitoes in various types of environments in the United States and in Russia found that between 5 and 20 percent of a mosquito population's genome is subject to evolutionary pressures at any given time - creating a strong signature of local adaptation to environment and humans.
"The entire history of modern medicine can be documented through the NEJM Archive."
IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.
› Verified 8 days ago
Corinne Phillips-ward, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1401 E H St, Mc Cook, NE 69001 Phone: 308-344-4110 Fax: 308-344-8369 | |
Kristin Marie Fulkerson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1401 E H St, Mc Cook, NE 69001 Phone: 308-344-4110 Fax: 308-344-8369 | |
Richard Klug, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1401 E H St, Mc Cook, NE 69001 Phone: 308-344-4110 Fax: 308-344-8369 | |
Dr. Hope Ann Ferguson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1401 E H St, Mc Cook, NE 69001 Phone: 308-344-8784 Fax: 308-344-8780 | |
Jason J Blomstedt, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1401 E H St, Mc Cook, NE 69001 Phone: 308-344-4110 Fax: 308-344-8369 | |
Dr. Matthew Nielsen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1401 E H St, Mc Cook, NE 69001 Phone: 308-344-4110 |